Product Data Sheet

VEGFR-2-IN-6

Cat. No.: HY-131658 444731-47-9 CAS No.: Molecular Formula: $C_{20}H_{21}N_{7}O_{2}S$ Molecular Weight: 423.49 **VEGFR** Target:

Pathway: Protein Tyrosine Kinase/RTK

Storage: Powder -20°C 3 years

In solvent

2 years -80°C 6 months

-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO: 25 mg/mL (59.03 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.3613 mL	11.8067 mL	23.6133 mL
	5 mM	0.4723 mL	2.3613 mL	4.7227 mL
	10 mM	0.2361 mL	1.1807 mL	2.3613 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.90 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (5.90 mM); Suspended solution; Need ultrasonic
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (5.90 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

VEGFR-2-IN-6 (example 64) is a VEGFR2 inhibitor (angiogenesis modulator), which is extracted from patent WO 02/059110^[1].

REFERENCES

[1]. Glaxo Wellcome House, et al. PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS. Patent WO 02/059110.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com